Prostatype Genomics
1.10 SEK
-2.65 %
Less than 1K followers
PROGEN
First North Stockholm
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Valuation
Income statement
Valuation
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Prostatype Genomics
EV/S
Median 2020-2022
P/B
Median 2020-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | - | 745.92 | 466.33 | 115.76 | 24.18 | 6.01 | 0.30 |
| Shares | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 12.4 | 59.2 |
| Market cap | - | 188.6 | 134.9 | 48.5 | 11.3 | 74.4 | 17.8 |
| Enterprise value | - | 174.2 | 115.8 | 40.3 | - | - | - |
| EV/S | - | 255.0 | 11,582.4 | 59.3 | - | - | - |
| EV/EBITDA | - | neg. | neg. | neg. | - | - | - |
| EV/EBIT | - | neg. | neg. | neg. | - | - | - |
| P/E | - | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | - | 6.67 | 3.76 | 1.85 | 0.46 | 2.22 | 0.67 |
| P/S | - | 276.1 | 13,488.7 | 71.3 | 8.3 | 372.1 | 29.9 |
| Dividend yield | - | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 48.6 % | 84.0 % | 89.3 % | 84.5 % | 50.1 % | 79.7 % | 52.2 % |
| Gearing ratio | 80.2 % | 5.2 % | 3.5 % | 3.3 % | - | - | 20.0 % |